Dignitana expands partnership with Celeritas to improve scalp cooling technology available in Mexico

Dignitana AB, manufacturer of The DigniCap® Scalp Cooling System, has expanded the agreement with Celeritas Trading to provide The DigniCap Delta model of the DigniCap Scalp Cooling System to minimize hair loss from chemotherapy for cancer patients in Mexico.  

Files for download
Dignitana Release - wkr0006.pdf

With the introduction of the DigniCap Delta model, patients will now have access to the next generation in scalp cooling technology – the thermoelectric cooling system and custom fit cooling wrap that is offered with the DigniCap Delta model.

Celeritas Trading has been Dignitana’s exclusive distributor in Mexico since 2009, currently offering DigniCap C3 at nine locations across the country. Celeritas has now purchased two DigniCap Delta devices.

“We are delighted to expand our offering in Mexico to now provide the most advanced scalp cooling technology available,” said Catarina Löwenadler, CEO of Dignitana.  “Celeritas has been a strong partner to Dignitana and we are pleased that patients in Mexico now have access to this latest technology to preserve dignity and quality of life during chemo.”

“The decision to transition from DigniCap C3 to DigniCap Delta was driven by patient demand for a clinically superior product,” said Susana Valdez, Principal of Celeritas Trading. “Hair loss during chemo impacts quality of life, and patients in Mexico want this life-changing therapy.”

DigniCap Delta is indicated for use with solid tumor cancers, and of these, Breast Cancer is the most prevalent globally.  Breast cancer is the second most common cancer in Mexico with over 30,000 new diagnoses each year. It accounts for 10.6% of all cancers and 16.4% of cancers in women in Mexico.

 


For More Information Contact 

Melissa Bourestom, Chief Communications Officer,  melissa.bourestom@dignitana.com  +1 469-518-5031


About Dignitana

Dignitana AB is the world leader in clinically superior scalp cooling technology. The company produces The DigniCap® Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and patient comfort. Hailed internationally as a life-changing medical advancement for cancer patients, The DigniCap Scalp Cooling System was invented in 1999 by a Swedish Oncology nurse and has been available in Europe since 2001.  Dignitana AB is listed on Nasdaq First North Growth Market in Sweden with headquarters in Lund, Sweden and US operations based in Dallas, Texas in the United States.  Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Certified Adviser is Redeye AB. Learn more at www.dignitana.com or www.dignicap.com